{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:29:50Z","timestamp":1790069390530,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81201277"],"award-info":[{"award-number":["81201277"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81271833"],"award-info":[{"award-number":["81271833"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81301421"],"award-info":[{"award-number":["81301421"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81471933"],"award-info":[{"award-number":["81471933"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Major Science and Technology Special Project of China","award":["2012ZX10002007-001-002"],"award-info":[{"award-number":["2012ZX10002007-001-002"]}]},{"name":"Major Science and Technology Special Project of China","award":["2013ZX10002001"],"award-info":[{"award-number":["2013ZX10002001"]}]},{"name":"\u201c973\u201d Project","award":["2012CB519001"],"award-info":[{"award-number":["2012CB519001"]}]},{"name":"Special Research Fund of Ministry of Health for Non-Profit Sector","award":["201302010"],"award-info":[{"award-number":["201302010"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.bbrc.2015.07.101","type":"journal-article","created":{"date-parts":[[2015,7,23]],"date-time":"2015-07-23T17:50:25Z","timestamp":1437673825000},"page":"1185-1191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Partial virological response to entecavir treatment in nucleos(t)ide-na\u00efve patients with HBeAg-positive chronic hepatitis B is not caused by reduced sensitivity"],"prefix":"10.1016","volume":"464","author":[{"given":"Xinyan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyue","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richeng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10 Suppl.\u00a03","key":"10.1016\/j.bbrc.2015.07.101_bib1","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1097\/00004836-200411003-00008","article-title":"Global epidemiology of hepatitis B virus","volume":"28","author":"Custer","year":"2004","journal-title":"J.\u00a0Clin. Gastroenterol."},{"key":"10.1016\/j.bbrc.2015.07.101_bib2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2015.07.101_bib3","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1002\/hep.22884","article-title":"Hepatitis B virus DNA levels and outcomes in chronic hepatitis B","volume":"49","author":"Chen","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2015.07.101_bib4","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1002\/hep.22920","article-title":"Benefits and risks of nucleoside analog therapy for hepatitis B","volume":"49","author":"Dienstag","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2015.07.101_bib5","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/17474124.2014.909724","article-title":"Current developments in nucleoside\/nucleotide analogues for hepatitis B","volume":"8","author":"Lo","year":"2014","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.bbrc.2015.07.101_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2893.2010.01274.x","article-title":"Management of chronic hepatitis B: experience from China","volume":"17","author":"Sun","year":"2010","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.bbrc.2015.07.101_bib7","doi-asserted-by":"crossref","first-page":"e1001082","DOI":"10.1371\/journal.ppat.1001082","article-title":"Generation of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner","volume":"6","author":"Kock","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bbrc.2015.07.101_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(04)00162-7","article-title":"Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection","volume":"64","author":"Zoulim","year":"2004","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bbrc.2015.07.101_bib9","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B","volume":"136","author":"Liaw","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrc.2015.07.101_bib10","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrc.2015.07.101_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/hep.22658","article-title":"Early hepatitis B virus DNA reduction in hepatitis B e antigen -positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir","volume":"49","author":"Leung","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2015.07.101_bib12","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleosidenaive patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2015.07.101_bib13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/jhep.2001.27563","article-title":"Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy","volume":"34","author":"Yuen","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2015.07.101_bib14","first-page":"p230A","article-title":"Telbivudine globe trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients","volume":"44","author":"Di Bisceglie","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2015.07.101_bib15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"European Association for the Study of the Liver","year":"2012","journal-title":"J.\u00a0Hepatol."},{"issue":"357","key":"10.1016\/j.bbrc.2015.07.101_bib16","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"2007","author":"Lai","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2015.07.101_bib17","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.22414","article-title":"Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"48","author":"Marcellin","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2015.07.101_bib18","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.cgh.2007.05.004","article-title":"Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B","volume":"5","author":"Keeffe","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrc.2015.07.101_bib19","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2015.07.101_bib20","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A\u00a0comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2015.07.101_bib21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/hep.24406","article-title":"Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response","volume":"54","author":"Zoutendijk","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2015.07.101_bib22","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3109\/00365521.2012.719927","article-title":"Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy","volume":"47","author":"Ko","year":"2012","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.bbrc.2015.07.101_bib23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MCG.0b013e318266fd31","article-title":"Response to higher dose of entecavir 1.0 mg daily in patients with partial response to entecavir 0.5 mg daily","volume":"47","author":"Ha","year":"2013","journal-title":"J.\u00a0Clin. Gastroenterol."},{"key":"10.1016\/j.bbrc.2015.07.101_bib24","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1111\/jvh.12239","article-title":"Antiviral effect of entecavir in nucleos(t)ide analogue-naive and nucleos(t)ide analogue-experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy","volume":"21","author":"Chen","year":"2014","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.bbrc.2015.07.101_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jviromet.2011.04.005","article-title":"Detection of lamivudine- or adefovir-resistant hepatitis B virus mutations by a liquid array","volume":"175","author":"Liu","year":"2011","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.bbrc.2015.07.101_bib26","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jhep.2008.01.027","article-title":"Impact of hepatitis B virus rtA181V\/T mutants on hepatitis B treatment failure","volume":"48","author":"Villet","year":"2008","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.bbrc.2015.07.101_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2003.07.003","article-title":"In\u00a0vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector","volume":"61","author":"Yang","year":"2004","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bbrc.2015.07.101_bib28","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1128\/JVI.64.6.2819-2824.1990","article-title":"Hepadnaviral envelope proteins regulate covalently closed circular DNA amplification","volume":"64","author":"Summers","year":"1990","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.bbrc.2015.07.101_bib29","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/hep.20388","article-title":"A\u00a0new strategy for studying in\u00a0vitro the drug susceptibility of clinical isolates of human hepatitis B virus","volume":"40","author":"Durantel","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2015.07.101_bib30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/135965350801300317","article-title":"Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants","volume":"13","author":"Carrouee-Durantel","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.bbrc.2015.07.101_bib31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2893.2009.01078.x","article-title":"Chronic hepatitis B: early viral suppression and longterm outcomes of therapy with oral nucleos(t)ides","volume":"16","author":"Nguyen","year":"2009","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.bbrc.2015.07.101_bib32","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/infdis\/jiu133","article-title":"Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response","volume":"210","author":"Wong","year":"2014","journal-title":"J.\u00a0Infect. Dis."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X15303314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X15303314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T22:24:15Z","timestamp":1652912655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X15303314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0006291X15303314"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2015.07.101","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Partial virological response to entecavir treatment in nucleos(t)ide-na\u00efve patients with HBeAg-positive chronic hepatitis B is not caused by reduced sensitivity","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2015.07.101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}